Sanofi Says Application For New Diabetes Drug, Lixisenatide, Under FDA Review

PARIS (Reuters) - European pharmaceuticals group Sanofi on Tuesday said its application for review for its new drug, lixisenatide, a diabetes treatment, had been accepted by the U.S. Food and Drug Administration.

(Reporting by Astrid Wendlandt)